Stockreport

Kymera Therapeutics Inc (KYMR) Reports Q4 and Full Year 2023 Financial Results [Yahoo! Finance]

Kymera Therapeutics, Inc.  (KYMR) 
PDF Research and Development Expenses : Rose to $53.0 million in Q4 and $189.1 million for the full year 2023. General and Administrative Expenses : Grew to $14.2 million [Read more]